Clinical Report: Ivermectin vs Permethrin for Scabies
Overview
A recent multicenter trial demonstrated that topical 5% permethrin cream achieved significantly higher clinical cure rates compared to oral ivermectin for classic scabies. The study found permethrin to be statistically superior at day 28, with ivermectin failing to meet noninferiority criteria.
Background
Scabies is a common skin infestation caused by the Sarcoptes scabiei mite, leading to significant morbidity due to itching and secondary infections. Effective treatment is crucial to alleviate symptoms and prevent transmission. Current guidelines recommend both permethrin and ivermectin as first-line treatments, making this comparative study particularly relevant for clinical practice.
Data Highlights
Group
Clinical Cure Rate (%)
Difference (%)
Ivermectin
71.8
-16.7
Permethrin
88.5
Key Findings
Permethrin demonstrated a clinical cure rate of 88.5% compared to 71.8% for ivermectin.
The difference in cure rates was statistically significant at -16.7 percentage points.
Among index cases, cure rates were 91.5% for permethrin versus 76.6% for ivermectin.
At the individual participant level, cure rates were 94.2% for permethrin and 85.3% for ivermectin.
Cutaneous adverse events occurred in 13.6% of permethrin cases and 9.9% of ivermectin cases.
The trial was conducted across 28 French hospitals with 1,092 participants.
Clinical Implications
The findings suggest that permethrin should be preferred over ivermectin for treating classic scabies due to its higher efficacy. Clinicians should consider factors such as patient adherence and potential side effects when selecting treatment options.
Conclusion
This study reinforces the superiority of permethrin over ivermectin for treating classic scabies, highlighting the need for careful consideration of treatment choices in clinical practice.
